Lymphocyte-activation gene 3, also known as LAG-3, is a protein that is has diverse biological effects on the functioning of T cells. This protein was first discovered in 1990. LAG-3 is an immune checkpoint receptor, and is thus used as the target of various drug development programs.

Increasing prevalence of chronic diseases such as cancer and autoimmune diseases such as AIDS are expected to increase the demand for treatment measures. This in turn, is expected to increase demand for lymphocyte-activation gene 3 protein, thus boosting growth of the lymphocyte-activation gene 3 market. Increasing number of pharmaceutical companies are seeking to develop new treatments for cancer and autoimmune disorders is expected to boost growth of the Lymphocyte-activation gene 3 protein market.

Get Sample copy of research report: https://www.worldwidemarketreports.com/sample/196105

Prima BioMed Ltd is a biotechnology company that is engaged in research, development, and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment with its core technologies based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

The lymphocyte-activation gene 3 market is gaining significant traction, owing to increasing research and development activities by various key players in the market.

F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies—announced successful dosing of the first patient with FS118 in a Phase I clinical trial. FS118 is a first-in-class bispecific antagonist simultaneously targeting LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1), two immune checkpoint molecules involved in tumor growth through attenuation of immune surveillance. FS118 showed potent anti-cancer activity in preclinical models, as recently presented by F-star at the 2018 AACR meeting.

Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/196105

In March 2015, a breakthrough in immunotherapy was recorded when the FDA approved Nivolumab as a second line treatment for metastatic lung squamous carcinoma. Nivolumab was previously known to be indicated for use among patients suffering from melanoma that is either not resectable or had not responded to other therapies.6, 7, 8, 10, not all PD‐1 or PD‐L1 positive patients show positive outcomes through this treatment of anti‐PD‐1 or PD‐L1 monoclonal antibody.

In 2014, GSK successfully was able to receive positive outcomes from its product GSK2831781, an anti LAG-3 drug, which proved to demonstrate positive results among healthy people and patients suffering from plaque psoriasis.

Browse more detail information about Lymphocyte Activation Gene 3 Protein Market Report at: https://www.worldwidemarketreports.com/market-insights/lymphocyte-activation-gene-3-protein-market

Bristol-Myers Squibb, also known as BMS, developed an Anti‐LAG‐3 drug. The company announced in 2017, that it successfully completed its preliminary efficacy trial for BMS-986016—an investigational anti-lymphocyte-activation gene 3 (LAG-3) therapy—in combination with Opdivo (nivolumab) for advanced melanoma. These patients were previously treated with anti-PD-1/PD-L1 therapy, however, showed no progress. While treatment with the new drug helped stop relapse melanoma among these patients. This development in turn, is expected to boost growth of the lymphocyte-activation gene 3 market.